Triple
T365501
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Medtronic |
E7950
|
entity |
| Predicate | hasDivision |
P35
|
FINISHED |
| Object |
Minimally Invasive Therapies Group
Minimally Invasive Therapies Group is a Medtronic business unit focused on developing and providing technologies and solutions for minimally invasive surgical and interventional procedures.
|
E46438
|
NE FINISHED |
How this triple was built (4 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Minimally Invasive Therapies Group | Statement: [Medtronic, hasDivision, Minimally Invasive Therapies Group]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Minimally Invasive Therapies Group Context triple: [Medtronic, hasDivision, Minimally Invasive Therapies Group]
-
A.
Committee for Advanced Therapies
The Committee for Advanced Therapies is a scientific body within the European Medicines Agency responsible for evaluating and providing expert opinions on advanced therapy medicinal products such as gene, cell, and tissue-engineered therapies.
-
B.
Center for Cellular and Molecular Therapeutics
The Center for Cellular and Molecular Therapeutics is a research institute specializing in developing gene and cell-based therapies for pediatric and genetic diseases.
-
C.
National Institute of Biomedical Imaging and Bioengineering
The National Institute of Biomedical Imaging and Bioengineering is a U.S. federal research institute that advances the development and application of biomedical imaging and bioengineering technologies to improve health.
-
D.
Division of Cancer Treatment and Diagnosis
The Division of Cancer Treatment and Diagnosis is a branch of the National Cancer Institute that supports the development, evaluation, and clinical testing of new cancer therapies and diagnostic tools.
-
E.
Center for Health and Biosciences
The Center for Health and Biosciences is a research and policy institute focused on health care, biomedical innovation, and related public policy issues.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg
Description generation
gpt-5.1
Instruction
Generate a one-sentence description of the target entity. You are given a context triple in the form (subject, predicate, object), where the object is the target entity. # Instructions Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. Avoid repeating the information from the triple, unless really essential. # Response Format Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: Minimally Invasive Therapies Group Triple: [Medtronic, hasDivision, Minimally Invasive Therapies Group]
Generated description
Minimally Invasive Therapies Group is a Medtronic business unit focused on developing and providing technologies and solutions for minimally invasive surgical and interventional procedures.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Minimally Invasive Therapies Group Target entity description: Minimally Invasive Therapies Group is a Medtronic business unit focused on developing and providing technologies and solutions for minimally invasive surgical and interventional procedures.
-
A.
Committee for Advanced Therapies
The Committee for Advanced Therapies is a scientific body within the European Medicines Agency responsible for evaluating and providing expert opinions on advanced therapy medicinal products such as gene, cell, and tissue-engineered therapies.
-
B.
Center for Cellular and Molecular Therapeutics
The Center for Cellular and Molecular Therapeutics is a research institute specializing in developing gene and cell-based therapies for pediatric and genetic diseases.
-
C.
National Institute of Biomedical Imaging and Bioengineering
The National Institute of Biomedical Imaging and Bioengineering is a U.S. federal research institute that advances the development and application of biomedical imaging and bioengineering technologies to improve health.
-
D.
Division of Cancer Treatment and Diagnosis
The Division of Cancer Treatment and Diagnosis is a branch of the National Cancer Institute that supports the development, evaluation, and clinical testing of new cancer therapies and diagnostic tools.
-
E.
Center for Health and Biosciences
The Center for Health and Biosciences is a research and policy institute focused on health care, biomedical innovation, and related public policy issues.
- F. None of above. chosen
Provenance (5 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69a2e7e880008190a6ad7e06e5d03007 |
completed | Feb. 28, 2026, 1:04 p.m. |
| NER | Named-entity recognition | batch_69a2ebe7d4d0819083daeb7686ae1914 |
completed | Feb. 28, 2026, 1:21 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69a3e8668b848190b68d19819ac134df |
completed | March 1, 2026, 7:19 a.m. |
| NEDg | Description generation | batch_69a3ea5beecc8190b128db693db39e95 |
completed | March 1, 2026, 7:27 a.m. |
| NED2 | Entity disambiguation (via description) | batch_69a3eba438548190912d5a4a9c0e6528 |
completed | March 1, 2026, 7:32 a.m. |
Created at: Feb. 28, 2026, 1:08 p.m.